Kura Oncology, Inc.
$9.23-4.8%YTD-5.4%1Y-5.7%
Price updated 3m ago·X counts updated 5d ago
On X
The complete picture of $KURA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
334X posts · last 7 days
Chatter Meter
0.9×
How loud $KURA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $KURA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $KURA.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $KURA
Neutral — Clinical-stage biotech with ziftomenib targeting KMT2A-rearranged AML and RAS-driven solid tumor cancers.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-2.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-57.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-444%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-10.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
10.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-142%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
94.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.77$-0.88+12.2%
Q1 2026May 12, 2026$-0.83$-0.88+5.7%
Q4 2025Mar 5, 2026$-0.92$-0.72-27.8%
Q3 2025Nov 4, 2025$-0.85$-0.57-49.1%
Next earningsTue, Nov 3·consensus EPS $-0.81
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$18.3M+29.5%96.6%-432%$-0.83$-86.0M
Q4 FY25$17.3M-67.8%100%-498%$-0.92$115.0M
Q3 FY25$20.8M—84.5%-386%$-0.85$-83.2M
Q2 FY25$15.3M—100%-475%$-0.75$-30.2M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$96.1M$84.9M – $132.7M-$3.22-$3.45 – -$2.9512
FY27$208.4M$139.9M – $416.7M-$2.41-$3.19 – -$1.5411
FY28$284.3M$162.0M – $732.1M-$1.94-$2.95 – -$0.1213
FY29$493.3M$335.1M – $1.0B-$0.23-$0.55 – -$0.1311
FY30$865.7M$588.1M – $1.8B$2.24$1.30 – $5.406
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.36%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-1.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 86.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.385-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeSep 88-K — Item 5.02: Officer or director change
AI summary
8-KOfficer or director changeJul 298-K — Item 5.02: Officer or director change
AI summary
8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary
+ 10 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 routine 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin InhibitorKura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes TranscriptCaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesCaspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $KURA on X in the last 7 days.